5 Best Gene Editing Stocks To Buy

4. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 27

Intellia Therapeutics, Inc. (NASDAQ:NTLA) was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The genome editing company focuses on the development of therapeutics for transthyretin amyloidosis, hereditary angioedema, acute myeloid leukemia, sickle cell disease, cancer, and autoimmune disorders. 

On October 11, Morgan Stanley analyst Terence Flynn initiated coverage ofIntellia Therapeutics, Inc. (NASDAQ:NTLA) with an Overweight rating and a $84 price target. Naming it “one of the leading genome editing companies,” the analyst noted that Intellia Therapeutics, Inc. (NASDAQ:NTLA) was the first to demonstrate the ability to edit a gene in the body, or “in vivo,” as compared to outside of the body, or “ex vivo.” 

According to Insider Monkey’s data, 27 hedge funds held stakes worth $853 million in Intellia Therapeutics, Inc. (NASDAQ:NTLA) at the end of Q2 2022, compared to 35 funds in the prior quarter worth $1.15 billion. Cathie Wood’s ARK Investment Management is the largest stakeholder of the company, with 9.5 million shares worth $439 million.  

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter.

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”